Business Wire

Viz.ai and Cercare Medical Partner to Support Neurovascular Clinical Decision Making

Share

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a partnership with Cercare Medical, which delivers next-level medical imaging with CT and MRI. The partnership will incorporate Cercare Perfusion, a fully-automated, simple-to-use, patient-specific perfusion software, into the Viz.ai platform.

“We are thrilled to join forces with another revolutionary technology company like Cercare,” said Steve Sweeny, vice president of business development and strategy at Viz.ai. “This partnership is another example of our continued commitment to work with leading, like-minded, innovative companies to enable quick access to important patient data and ultimately improve clinical impact with our Viz platform.”

Viz is broadening its imaging features and functionality to best serve institutions that perform MR imaging in the patient workflow. The infusion of Cercare Perfusion technology into the Viz.ai platform enhances the company’s flagship AI-powered neurovascular portfolio as well as the platform’s capabilities.

Brain perfusion scans measure blood flow in the brain and are used to provide critically needed information on the extent of tissue damage due, for instance, to acute ischemic stroke.1 Quickly mapping brain perfusion deficits is pivotal to minimize tissue damage in acute stroke management, and Cercare further enriches the workflow with layers of AI to produce volumetric measures, which directly impact clinical decision-making.2

“Viz.ai and Cercare Medical share the commitment to support clinical decision-making to enable the best possible patient care,” said Kim Beuschau Mouridsen, CEO of Cercare Medical. “We are pleased to enter into this global partnership to increase access to the latest perfusion technology, which is designed to easily integrate into existing workflows to provide healthcare professionals with deep, fast, and reliable patient insights.”

Cercare uniquely provides maps illustrating oxygen availability, in addition to blood flow and volume. This allows more detailed assessment of tissue pathology and therefore optimized patient management for a variety of conditions, such as dementia and neoplasia.

About Viz.ai, Inc.

Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care, covering more than 200 million lives across 1,200+ hospitals and health systems in the U.S. and Europe. The AI-powered Viz Platform is an intelligent care coordination solution that identifies more patients with a particular disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by clinical data, the Viz Platform delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit viz.ai.

About Cercare Medical

Founded as a spin-out from Aarhus University, Denmark in 2013, by leading experts in perfusion imaging and AI, Cercare Medical delivers the potential of perfusion imaging with a fully-automated and multi-vendor compatible software solution for CT and MRI Perfusion imaging post-processing. Our focus, based on the mechanism of a disease, the apprehension and detection of primary and collateral symptoms of microvascular conditions, allows clinicians to develop a final interpretation for both diagnosis support and patient follow-up. For more information, visit https://cercare-medical.com/

1 Dynamics of cerebral perfusion and oxygenation parameters following endovascular treatment of acute ischemic stroke
BMJ Journals
https://jnis.bmj.com/content/14/1/neurintsurg-2020-017163

2 The Role of the Cerebral Capillaries in Acute Ischemic Stroke: The Extended Penumbra Model
Sage Journals
https://journals.sagepub.com/doi/10.1038/jcbfm.2013.18

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Erich Sandoval
erich.sandoval@finnpartners.com
+1 917 497 2867

Franck Ruiz
franck@cercare-medical.com
+33 660 887 452

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda Completes Acquisition of Nimbus Therapeutics’ TYK2 Program Subsidiary9.2.2023 02:30:00 EET | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that it has completed an acquisition of all shares of Nimbus Lakshmi, Inc. (“Lakshmi”) from Nimbus Therapeutics, LLC (“Nimbus”), on February 8, 2023 (EST), as set forth in the share purchase agreement, following clearance from the United States Federal Trade Commission and a satisfaction of other closing conditions. The agreement had been announced on December 13, 2022: “Takeda to Acquire 100% Ownership of Nimbus Therapeutics’ TYK2 Program Subsidiary”. Following the completion of this transaction, Takeda has now acquired TAK-279, formerly known at Nimbus as NDI-034858. With Phase 2b data to be presented in Q4 FY2022 and Phase 3 study in psoriasis expected to start in 2023, TAK-279 has the potential to demonstrate best-in-class efficacy, safety and convenience in psoriasis as well as multiple other immune-mediated diseases, including inflammatory bowel disease, psoriatic arthritis and systemic lupus erythematosus. This acquisition strengthens T

O-RAN ALLIANCE Events and Demos at MWC Barcelona Showcasing O-RAN Ecosystem Progress9.2.2023 02:24:00 EET | Press release

Join us for O-RAN ALLIANCE Ecosystem Briefing, February 28, 2023 at MWC Barcelona This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230208005994/en/ O-RAN ALLIANCE plans to hold its next industry event on Tuesday, February 28, 2023 from 15:30-16:30 CET at the Deutsche Telekom booth (Hall 3, Stand 3M31). The event will include: An update on O-RAN’s progress and future directions by Alex Jinsung Choi, Chair of the Board of O-RAN ALLIANCE and SVP Group Technology at Deutsche Telekom Stefan Engel-Flechsig, O-RAN ALLIANCE COO Views on important areas supporting widespread adoption of open RAN, featuring leading operators from Asia, Europe and the Americas: Open RAN testing and integration – by Chih-Lin I, Chief Scientist from China Mobile and Co-chair of O-RAN Technical Steering Committee Open RAN security – by Claire Chauvin, Strategy Architecture and Standardization Director at Orange Open software for the RAN – by Rob Soni, VP RA

IFF Reports Fourth Quarter and Full Year 2022 Results9.2.2023 00:31:00 EET | Press release

International Flavors & Fragrances Inc. (NYSE: IFF) reported financial results for the fourth quarter and full year ended December 31, 2022. Management Commentary “IFF delivered solid financial results in 2022 in what continues to be a challenging operating environment,” said IFF CEO Frank Clyburn. “Throughout the year our team successfully executed on what we could control – pricing, productivity and portfolio optimization – to generate strong sales growth, enhance profitability and reduce our debt. At the same time, we introduced a refreshed growth-focused strategy, that deepens our commitment to customers, prioritizes our highest-return businesses, and expands productivity to drive long-term profitable growth. We are confident that these are the right strategies to navigate near-term challenges – as we balance growth, profitability and cash flow generation – and deliver long-term value creation for our shareholders.” Fourth Quarter 2022 Consolidated Financial Results Reported net sa

Global Partners Announce Innovations for Marine Managers to Help Our Oceans With Private Sector Support From Mary Kay Inc.8.2.2023 20:03:00 EET | Press release

Ocean conservation managers and practitioners, global experts, and high-level officials are convening for the Fifth International Marine Protected Area Congress (IMPAC5) from February 3-9 in Vancouver, Canada, to take a stand to protect the ocean. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230208005180/en/ MPAth, short for Marine Protected Area Tool Hub, is a free online resource for seascape stakeholders at every level. It uses the same problem-solving matrix honed by marine experts to guide users through a learning journey and help them address their most pressing challenges on sustainable livelihoods, financing, effectiveness, and climate change. (Credit: UN Environment Programme) IMPAC5 is known as the preeminent conference for the exchange of knowledge within the global community of marine conservation managers, practitioners, and decision makers. It provides the opportunity to highlight the latest science and share

Morgan Stanley Hosts First Global Demo Day for Startups in Inclusive Ventures Lab8.2.2023 18:23:00 EET | Press release

Morgan Stanley (NYSE: MS) today is hosting its first global in-person Demo Day, with 10 participating companies from the US and Europe, the Middle East and Africa (EMEA). The cohort companies, all founded by women, will pitch over 200 investors, as well as potential business partners and customers. Over the past five months, Morgan Stanley’s Inclusive Ventures Lab has supported its eighth cohort of technology-enabled startups in the post-seed to Series A funding round stage, offering an intensive accelerator program designed to provide a variety of mentorship opportunities and business-growth resources from across the Firm’s network. “We are on a mission to change the investing landscape for underrepresented founders. Through our accelerator program we are providing promising startups with much-needed capital, the broad resources of Morgan Stanley and access to investors,” said Selma Bueno, Managing Director and Global Head of the Inclusive Ventures Group. “Today’s Demo Day showcases i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom